# Remifentanil reduces post-induction hypotension compared to fentanyl in thoracoscopic esophagectomy: a retrospective cohort study

**Authors:** Jin Zhang, Chen Zhao, Hao Sun, Youming Deng, Guangfu Qian, Shibing Teng, Baoxin Wang

PMC · DOI: 10.3389/fphar.2025.1660228 · 2025-10-09

## TL;DR

Using remifentanil instead of fentanyl during anesthesia induction lowers the risk of low blood pressure after surgery in high-risk patients.

## Contribution

This study provides new evidence that remifentanil reduces post-induction hypotension compared to fentanyl in thoracoscopic esophagectomy patients.

## Key findings

- Remifentanil reduced post-induction hypotension incidence compared to fentanyl (23.7% vs. 42.3%).
- Remifentanil was associated with more stable blood pressure and less variability in the first 15 minutes post-induction.
- Bradycardia was more common with remifentanil, while fentanyl was linked to more post-intubation hypertension.

## Abstract

Post-induction hypotension (PIH) is a common complication associated with anesthesia, particularly in high-risk groups, such as elderly, malnourished patients with multiple comorbidities undergoing thoracoscopic esophagectomy. The selection of induction agents plays a significant role in influencing hemodynamic stability. However, there is a lack of comprehensive comparative data regarding the impact of different opioid agents on PIH.

This retrospective cohort study included 289 patients undergoing thoracoscopic esophagectomy, who received etomidate combined with either fentanyl (Fentanyl group) or remifentanil (Remifentanil group) for anesthesia induction. A logistic regression model was used to examine the association between the induction regimen and PIH. Confounding factors were adjusted using a directed acyclic graph, and least absolute shrinkage and selection operator (LASSO) regression was employed to select covariates, ensuring robustness of the primary outcome analysis. Hemodynamic changes in systolic blood pressure, mean arterial pressure, and heart rate during the first 15 min post-induction were analyzed using generalized estimating equations to account for correlated observations. Subgroup analyses were performed for key clinical subgroups.

Among 289 patients analyzed, the incidence of PIH was significantly lower in the Remifentanil group compared to the Fentanyl group (23.7% vs. 42.3%, P = 0.001; adjusted odds ratio (OR) = 0.42, 95% confidence interval (CI): 0.25–0.73). Sensitivity analysis using LASSO-selected covariates yielded consistent results (adjusted OR = 0.41, 95% CI: 0.22–0.69, P = 0.001). Bradycardia occurred more frequently with remifentanil (11.9% vs. 4.5%, P = 0.03), whereas post-intubation hypertension and phenylephrine use were higher in the fentanyl group. No significant differences were observed in cardiovascular complications or postoperative hospital stay. Subgroup analyses revealed no significant effect modification across age, hemoglobin, or albumin levels. Remifentanil was also associated with more stable hemodynamics, including attenuated systolic blood pressure decline and lower variability during the first 15 min post-induction.

Remifentanil-based general anesthesia induction reduces the risk of PIH and enhances hemodynamic stability in patients undergoing thoracoscopic esophagectomy.

## Linked entities

- **Chemicals:** remifentanil (PubChem CID 60815), fentanyl (PubChem CID 3345), phenylephrine (PubChem CID 4782)

## Full-text entities

- **Genes:** ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}
- **Diseases:** Bradycardia (MESH:D001919), PIH (MESH:D057774), hypotension (MESH:D007022), hypertension (MESH:D006973), cardiovascular complications (MESH:D002318), malnourished (MESH:D044342)
- **Chemicals:** phenylephrine (MESH:D010656), Remifentanil (MESH:D000077208), etomidate (MESH:D005045), Fentanyl (MESH:D005283)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12546277/full.md

---
Source: https://tomesphere.com/paper/PMC12546277